News | 23 January 2013
Oncothyreon (NASDAQ:ONTY) experiences a ratings drop this week, going from last week's D to an F. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F's in Earnings Growth, Equity, and ...
Click on the link to read the full article at Investorplace.com
(This link will open in a new window)